Log in

Start Your Membership Now

Labcorp announced the availability of the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first blood-based in-vitro diagnostic (IVD) test cleared by the U.S. Food and Drug Administration (FDA) to aid in the diagnosis of Alzheimer's disease through early detection. Developed by Fujirebio Diagnostics, Inc., the test is now available nationwide through Labcorp, the announcement stated.

The test offers results that are comparable to existing methods that support a diagnosis of Alzheimer's disease–cerebrospinal fluid (CSF) testing obtained through lumbar puncture and positron emission tomography (PET) scans–but from a simple blood draw, making it . . .

Want To Read More? Log In Or Become A Free Member
Resource Available For All OPEN MINDS Circle Members
Log In
If you are already a member, log in to your account to access this resource and more.

Become A Free Member
You can become a free member and get access now. Learn more about the OPEN MINDS Circle Market Intelligence Service Membership. Reach out to our team at info@openminds.com, or call us at 877-350-6463.

A Paid OPEN MINDS Circle Membership provides unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!

Treatment Innovation & Treatment Technology